20 febrero 2008
19 febrero 2008
Phase I Clinical and Pharmacokinetic Study of Kahalalide F Administered Weekly as a 1-Hour Infusion to Patients with Advanced Solid Tumors .
Resultados de Fase I en Tumores Solidos y Dosis Recomendada para la Fase II .
18 febrero 2008
Editorial Zeltia publica el Tercer Volumen : El Mundo Submarino - Volumen 3 .
Tras suponer una exitosa venta de los dos primeros volumenes ....sale a la venta el Tercer Volumen .... veremos si en la cuenta de resultados del 2007 nos sorprenden .
Título: El Mundo Submarino de PharmaMar -Volumen 3
ISBN: 978-84-611-8677-8
Edita: Zeltia, S.A. c/ José Abascal, 2 – 28003 Madrid - Teléfono: +34 91 444 4500
Presentación: Tapa dura
Precio: 60,00 € (IVA incluido) Peninsula y Baleares.
Aplidin de Pharma Mar y ARA - C de Pfizer tienen Sinergia en Limfoma y Leucemia , in Vitro e in Vivo .
En Relacion :
Aplidin synergizes with cytosine arabinoside: functional relevance of mitochondria in Aplidin-induced cytotoxicity.Humeniuk R, Menon LG, Mishra PJ, Saydam G, Longo-Sorbello GS, Elisseyeff Y, Lewis LD, Aracil M, Jimeno J, Bertino JR, Banerjee D.
Department of Medicine and Pharmacology, The Cancer Institute of New Jersey, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, New Brunswick, NJ 08903, USA.
Aplidin (plitidepsin) is a novel marine-derived antitumor agent presently undergoing phase II clinical trials in hematological malignancies and solid tumors. Lack of bone marrow toxicity has encouraged further development of this drug for treatment of leukemia and lymphoma. Multiple signaling pathways have been shown to be involved in Aplidin-induced apoptosis and cell cycle arrest in G1 and G2 phase. However, the exact mechanism(s) of Aplidin action remains to be elucidated. Here we demonstrate that mitochondria-associated or -localized processes are the potential cellular targets of Aplidin. Whole genome gene-expression profiling (GEP) revealed that fatty acid metabolism, sterol biosynthesis and energy metabolism, including the tricarboxylic acid cycle and ATP synthesis are affected by Aplidin treatment. Moreover, mutant MOLT-4, human leukemia cells lacking functional mitochondria, were found to be resistant to Aplidin. Cytosine arabinoside (araC), which also generates oxidative stress but does not affect the ATP pool, showed synergism with Aplidin in our leukemia and lymphoma models in vitro and in vivo. These studies provide new insights into the mechanism of action of Aplidin. The efficacy of the combination of Aplidin and araC is currently being evaluated in clinical phase I/II program for the treatment of patients with relapsed leukemia and high-grade lymphoma.
Aplidin synergizes with cytosine arabinoside: functional relevance of mitochondria in Aplidin-induced cytotoxicity.Humeniuk R, Menon LG, Mishra PJ, Saydam G, Longo-Sorbello GS, Elisseyeff Y, Lewis LD, Aracil M, Jimeno J, Bertino JR, Banerjee D.
Department of Medicine and Pharmacology, The Cancer Institute of New Jersey, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, New Brunswick, NJ 08903, USA.
Aplidin (plitidepsin) is a novel marine-derived antitumor agent presently undergoing phase II clinical trials in hematological malignancies and solid tumors. Lack of bone marrow toxicity has encouraged further development of this drug for treatment of leukemia and lymphoma. Multiple signaling pathways have been shown to be involved in Aplidin-induced apoptosis and cell cycle arrest in G1 and G2 phase. However, the exact mechanism(s) of Aplidin action remains to be elucidated. Here we demonstrate that mitochondria-associated or -localized processes are the potential cellular targets of Aplidin. Whole genome gene-expression profiling (GEP) revealed that fatty acid metabolism, sterol biosynthesis and energy metabolism, including the tricarboxylic acid cycle and ATP synthesis are affected by Aplidin treatment. Moreover, mutant MOLT-4, human leukemia cells lacking functional mitochondria, were found to be resistant to Aplidin. Cytosine arabinoside (araC), which also generates oxidative stress but does not affect the ATP pool, showed synergism with Aplidin in our leukemia and lymphoma models in vitro and in vivo. These studies provide new insights into the mechanism of action of Aplidin. The efficacy of the combination of Aplidin and araC is currently being evaluated in clinical phase I/II program for the treatment of patients with relapsed leukemia and high-grade lymphoma.
15 febrero 2008
Iberia podría crear un frente común junto con Clickair, Vueling , Spanair y Air Nostrum .
El Cartel de " Se vende " cuelga de los cielos Españoles .
Publicado hoy en el Expansión .
Escribe Alberto Marimón .
A lo largo de 2008 se van a producir importantes movimientos en la estructura accionarial de las grandes aerolineas Españolas que va a modificar sustancialmente el mapa de los cielos .
El grupo escadinavo SAS cerrara la venta de Spanair ; y Vueling y Clikair empresa participada por Iberia , Air Nostrum ,Quercus- Agroalimen que ya han iniciado contactos para sopesar su Fusion y crear un Gigante Español de los vuelos de bajo coste .
Detras de todas estas operaciones sobresale el nombre propio de Iberia que podría crear un frente comun junto con Clickair, Vueling , Spanair y Air Nostrum .
La unión de Clickair y Vueling tendria como accionista de referencia a Iberia , ademas de Air Nostrum , que posee desde hace años un acuerdo de franquicia con la empresa presidida por Feranado Conte .
A falta de conocer el resultado final , las aerolineas han frenado este ejercicio sus planes comerciales para tratar de poner un poco de orden en el mercado .
Paralelamente a la consolodacion del mercado nacional , queda en el aire la esperada fusión de Iberia con un gran grupo Europeo . Sus directivos llevan años apostando por protagonizar un papel decisivo en el proceso de concentración en Europa , ya sea con British Airways , su socio industrial , o con Air France o a Lufthansa . Sin embargo , lo que toca a hora es poner orden en los cielos nacionales .
14 febrero 2008
NeuroPharma sera la primera en asistir a un Congreso de Relevancia Internacional de Alzheimer .
2008 Feb 12
Preclinical efficacy on GSK-3 inhibitors: Towards a future generation of powerful drugs .
Martinez A.
NeuroPharma, Avda de la Industria 52, 28760 Madrid, Spain.
The renewed interest in glycogen synthase kinase-3 (GSK-3), involved in the molecular pathogenesis of human severe diseases, is focused on the potential of its inhibitors to treat diseases that have significant limitations in their current treatments. During the last 5 years, a lot of literature discuss progress in the search and pharmacological actions of GSK-3 inhibitors, but now, evidence have been accumulated showing preclinical efficacy for these new drugs, in very different models of several distinct pathologies. These studies have been summarized in the present review offering promising examples for new therapies for diabetes, cancer, inflammation, Alzheimer's disease and other neurological pathologies, and mood disorders. Now, clinical human trials are awaiting to confirm the ray of hope that GSK-3 inhibitors are arising for the future treatment of severe unmet diseases. (c) 2008 Wiley Periodicals, Inc. Med Res Rev.
13 febrero 2008
Copyr ... empresa perteneciente al Grupo Zeltia en Italia .
Copyr nasce nel 1961 come Compagnia del Piretro. Da allora il core business dell'azienda è rappresentato dalla formulazione di insetticidi a base di piretro e piretroidi efficaci e con un elevato profilo di sicurezza.
Con l'accresciuta sensibilità alle tematiche ambientali e l'attenzione alla sicurezza di operatori e consumatori, le conoscenze maturate da Copyr nello sviluppo di formulati di derivazione naturale hanno contribuito al consolidamento della propria posizione di leadership sul mercato nazionale e alla continua proposta di nuovi prodotti e settori di applicazione.
A maggio 2006 Copyr viene acquisita da Zelnova S.A., entrando in tal modo a far parte del Gruppo Zeltia.
12 febrero 2008
Aplidin - Melanoma . Articulo en el "" The Journal Pharmacology and experimental Therapeutics "" en su edicion de Marzo .
Plitidepsin has a dual effect inhibiting cell cycle and inducing apoptosis via Rac1/JNK activation in human melanoma cells.
Munoz-Alonso MJ, Gonzalez-Santiago L, Zarich N, Martinez T, Alvarez E, Rojas JM, Munoz A
Instituto de Investigaciones Biomedicas "Alberto Sols" CSIC and Pharma Mar SA.
Melanoma is the most aggressive skin cancer and a serious health problem worldwide because of its increasing incidence and the lack of satisfactory chemotherapy for late stages of the disease. The marine depsipeptide plitidepsin (Aplidin((R))) is an anti-tumoral agent under Phase II clinical development against several neoplasias including melanoma. We report that plitidepsin has a dual effect on the human SK-MEL-28 and UACC-257 melanoma cell lines: at low concentrations (
Munoz-Alonso MJ, Gonzalez-Santiago L, Zarich N, Martinez T, Alvarez E, Rojas JM, Munoz A
Instituto de Investigaciones Biomedicas "Alberto Sols" CSIC and Pharma Mar SA.
Melanoma is the most aggressive skin cancer and a serious health problem worldwide because of its increasing incidence and the lack of satisfactory chemotherapy for late stages of the disease. The marine depsipeptide plitidepsin (Aplidin((R))) is an anti-tumoral agent under Phase II clinical development against several neoplasias including melanoma. We report that plitidepsin has a dual effect on the human SK-MEL-28 and UACC-257 melanoma cell lines: at low concentrations (
11 febrero 2008
Yondelis , Protocolo de la Fase II Pediatrica .
Protocol :
COG-ADVL0221
Lead Group:
COG
Protocol Title:
"A Phase II Study of ET-743 in Children with Recurrent Sarcomas"
CIRB Initial Review Date :
2/24/2005
Group Activation Date :
1/28/2008
Expiration Date :
1/20/2009
PD : A tener en cuenta que la EMEA en su aprobación del Yondelis ... en su EPAR ....dispuso que el Yondelis no podría ser administrado a Menores hasta obtener "" Más datos "" ... por lo tanto es crucial que desde los EEUU se haya iniciado esta Fase II por el Children's Oncology Group
( COG ) Y el National Cancer Institute ( NCI ) ...con fecha de termino en Enero 2009 .....de conseguirse esos datos que pide la EMEA , esta autorizaria su aplicacion en Menores ....lo cual dejaria muy por debajo las previsiones de Sousa de obtener 100 Millones de euros en Europa .....dicha cifra se incrementaria en varias veces debido a que hay muchos mas casos de sarcoma en menores que en Adultos .
10 febrero 2008
Zeltia reconoce que su bajo precio la hace atractiva ante una posible oferta de Compra . Comunica tambien que sacara a NeuroPharma a bolsa en 2009 .
....termina el articulo con lo que a mi al menos me gustaria ....y es que entrara alguien en el Capital de manera Amistosa .....:
........por lo que la compañía cree que las ofertas que no tuvieran carácter amistoso lo tendrían difícil para prosperar.
........por lo que la compañía cree que las ofertas que no tuvieran carácter amistoso lo tendrían difícil para prosperar.
Suscribirse a:
Entradas (Atom)